Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research1,190

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1121–1140 of 1,190 studiesSort:

CompletedInterventional · Phase 1/2NCT05603312 ↗
A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease
Harini SarvaPI
Intervention
Genetic: AAV-GAD Low Dose · Genetic: AAV-GAD High Dose · Procedure: Sham Surgery
Dates

FiltersClear all

Status

Recruiting350
Not yet recruiting11
Enrolling by invitation17
Active, not recruiting322
Completed358
Terminated132

Study type

Interventional1,190
Observational101
Expanded access19
Not on ClinicalTrials.gov1,519

Phase

Phase 3325
Not applicable304
Phase 2286
Phase 1103
Phase 1/277
Phase 454

Investigator

Gail J Roboz41
Manish A Shah27
Parag Goyal23
Sonal Kumar23
Scott T. Tagawa22

Show all 50Show fewer

Department

Medicine750
Pediatrics81
Neurology46
Psychiatry46
Obstetrics and Gynecology41

Show all 22Show fewer

Condition

Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31
Neoplasms31

Show all 50

Intervention type

Drug788
Other176
Device166
Biological150
Procedure119
Behavioral83

Sponsor type

Industry685
WCM (investigator-initiated)230
Other academic173
NIH76
Cooperative group25
Unknown1

Start date

Has results posted342

Interventional×Clear all

Showing 1121–1140 of 1,190 studiesSort:

CompletedInterventional · Phase 1/2NCT05603312 ↗
A Randomized, Double-Blind, Sham-Controlled Study to Evaluate the Safety and Tolerability of Glutamic Acid Decarboxylase Gene Transfer to the Subthalamic Nuclei in Participants With Parkinson's Disease
Harini SarvaPI
Intervention
Genetic: AAV-GAD Low Dose · Genetic: AAV-GAD High Dose · Procedure: Sham Surgery
Dates

Phase 2/3

Early phase 13

Harini Sarva21
Ashish Saxena20
Cora Sternberg20
Ellen K. Ritchie18
Ruben Niesvizky16
Dana Jeremy Lukin14
Evelyn M. Horn14
Pinkal Desai14
Ellen J Scherl13
Daniel W Skupski12
Eleni Andreopoulou12
Jim W. Cheung12
Jia Ruan12
Massimo Cristofanilli12
Sujit Sheth12
Catherine Butkus Small11
James E. Ip11
John Allan11
Anna C Pavlick10
Alexander Ja-Ho Chou10
Aliza B Solomon10
Alpana P. Shukla10
Marshall J. Glesby10
Anna Podolanczuk9
Barbara Ma9
Catherine McGuinn9
Silvia Chiara Formenti9
Hani Lamie Ashamalla9
Kristen Marks9
Robert J. Kaner9
Shari Lipner9
Maria Teresa DeSancho8
Samuel Kim8
Andrew F. Alexis7
Erin Mulvey7
Evelyn Cantillo7
Jean W. Pape7
Sebastian A. Mayer7
Brian DeRubertis6
Conor Liston6
Darshana M Dadhania6
David M Nanus6
Joseph M Scandura6
Lok W. Yung6
Mehraneh Dorna Jafari6

Neurological Surgery19

Cardiothoracic Surgery17

Urology15

Rehabilitation Medicine13

Population Health Sciences9

Otolaryngology Head and Neck Surgery7

Pathology and Laboratory Medicine1

Pharmacology1

Show fewer

Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Neoplasm Metastasis23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Radiation

Diagnostic test22

Dietary supplement14

Combination product11

Genetic6

Oct 2022 – Sep 2024· Results posted

Sponsor

MeiraGTx, LLC

Parkinson's Disease

TerminatedInterventional · Phase 3NCT05605093 ↗

Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor

Matthew William McCarthyPIAlexander DrelickPI

Intervention: Drug: Shionogi Protease Inhibitor (S-217622) · Drug: placebo
Dates: Dec 2022 – Oct 2025· Results posted
Sponsor: University of Minnesota

COVID-19

CompletedInterventional · Phase 3NCT05614063 ↗

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Padmaja KandulaPI

Intervention: Drug: XEN1101 · Drug: Placebo
Dates: Nov 2022 – Jan 2026
Sponsor: Xenon Pharmaceuticals Inc.

Focal Onset Seizures

CompletedInterventional · Phase 2NCT05616013 ↗

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight or Obese Men and Women

Louis J AronnePI

Intervention: Biological: Bimagrumab · Drug: Semaglutide · Other: Placebo
Dates: Nov 2022 – May 2024· Results posted
Sponsor: Versanis Bio

ObesityObeseOverweight or Obesity

TerminatedInterventional · Phase 1/2NCT05617040 ↗

A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

Cora SternbergPI

Intervention: Biological: ChAdOx1-PCAQ · Biological: MVA-PCAQ
Dates: Jan 2023 – Feb 2025· Results posted
Sponsor: Vaccitech (UK) Ltd.

Prostate Cancer

TerminatedInterventional · Phase 1NCT05618366 ↗

Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma

Erin MulveyPI

Intervention: Drug: Venetoclax · Drug: Tazemetostat
Dates: Jun 2023 – Feb 2026
Sponsor: Weill Medical College of Cornell University

Lymphoma, Non-HodgkinDiffuse Large B Cell LymphomaFollicular Lymphoma

CompletedInterventional · Phase 2NCT05630183 ↗

A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)

Allyson J OceanPI

Intervention: Drug: Botensilimab · Drug: Gemcitabine · Drug: Nab-paclitaxel
Dates: Mar 2023 – Jan 2026
Sponsor: Agenus Inc

Metastatic Pancreatic Ductal Adenocarcinoma

CompletedInterventional · Phase 2NCT05630885 ↗

A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Marshall J. GlesbyPI

Intervention: Drug: CVC 150 mg · Drug: CVC 300 mg · Other: Placebo for CVC 150 mg · Other: Placebo for CVC 300 mg
Dates: May 2023 – Jun 2024· Results posted
Sponsor: National Institute of Allergy & Infectious Diseases

HIV-1-infectionElevated Cardiovascular Risk

TerminatedInterventional · Phase 3NCT05636176 ↗

Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Parag GoyalPI

Intervention: Drug: Ziltivekimab · Drug: Placebo
Dates: May 2023 – Sep 2026
Sponsor: Novo Nordisk Pharmaceuticals, Inc.

Heart Failure

TerminatedInterventional · Phase 2NCT05643638 ↗

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of CYP-001 in Combination With Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease

Tsiporah B ShorePI

Intervention: Biological: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs) · Biological: Placebo · Drug: Corticosteroids
Dates: Mar 2024 – Mar 2026
Sponsor: Cynata Therapeutics

Graft Versus Host Disease, Acute

TerminatedInterventional · Phase 3NCT05665595 ↗

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

Anna C PavlickPI

Intervention: Biological: Pembrolizumab/Vibostolimab · Biological: Pembrolizumab
Dates: Jan 2023 – Mar 2024· Results posted
Sponsor: Merck & Co., Inc.

Melanoma

CompletedInterventional · Phase 2NCT05669001 ↗

A 12-Month, Randomized, Open-Label, Phase IIA Study Evaluating the Safety and Efficacy of Siplizumab in Combination With Belatacept and MPA Compared to Standard of Care Immunosuppression in de Novo Renal Transplant Recipients (ASCEND)

Darshana M DadhaniaPI

Intervention: Biological: TCD601 · Biological: belatacept · Drug: ATG · Drug: TAC · Drug: MPA · Drug: Corticosteroids
Dates: Dec 2023 – Apr 2026
Sponsor: ITB-MED LLC

Renal Transplantation

CompletedInterventional · Phase 2NCT05673811 ↗

A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Alana NguyenPI

Intervention: Drug: Nab-paclitaxel · Drug: Gemcitabine · Genetic: VCN-01
Dates: Jan 2023 – Mar 2025· Results posted
Sponsor: Theriva Biologics, Inc.

Pancreatic AdenocarcinomaMetastatic

CompletedInterventional · Not applicableNCT05699499 ↗

Analysis of Impact of KeryFlex on Quality of Life for Retronychia or Lichen Planus Adult Patients

Shari LipnerPI

Intervention: Other: KeryFlex
Dates: Apr 2023 – Sep 2023
Sponsor: Weill Medical College of Cornell University

Lichen Planus of Nail

CompletedInterventional · Not applicableNCT05701163 ↗

Assessing the Effect of Abstinence Period on Semen Parameters

Jonathan GalPI

Intervention: Other: Abstinence followed by semen sample collection.
Dates: Apr 2023 – Feb 2028 (est.)
Sponsor: Weill Medical College of Cornell University

Infertility, Male

CompletedInterventional · Phase 3NCT05704738 ↗

A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Andrew F. AlexisPI

Intervention: Drug: Rocatinlimab · Drug: Placebo
Dates: Apr 2023 – Feb 2025· Results posted
Sponsor: Amgen, Inc.

Atopic Dermatitis

CompletedInterventional · Phase 4NCT05711524 ↗

Pilot Clinical Trial of Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen (INTERCEPT Fibrinogen Complex) in Patients With Bleeding to Expedite Product Availability and Improve Outcomes in Perioperative Bleeding

Melissa CushingPI

Intervention: Biological: Traditional Cryoprecipitate · Biological: Pathogen-Reduced Cryoprecipitate
Dates: Apr 2023 – Oct 2024· Results posted
Sponsor: Weill Medical College of Cornell University

HypofibrinogenemiaBleeding

CompletedInterventional · Phase 2NCT05714969 ↗

A Phase 2b, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of TAK-755 (rADAMTS13) With Minimal to No Plasma Exchange (PEX) in the Treatment of Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Maria Teresa DeSanchoPI

Intervention: Biological: TAK-755
Dates: Jul 2023 – Apr 2026
Sponsor: Takeda Development Center Americas, Inc.

Thrombotic Thrombocytopenic Purpura (TTP)

TerminatedInterventional · Not applicableNCT05747027 ↗

Prospective Randomized Controlled Trial Comparing Transvaginal Rectopexy and Ventral Mesh Rectopexy for Obstructed Defecation in Pelvic Organ Prolapse (PROD Trial)

Tirsit Shiferaw AsfawPI

Intervention: Procedure: Laparoscopic abdominal ventral rectopexy · Procedure: Transvaginal sacrospinous rectopexy
Dates: May 2024 – May 2025· Results posted
Sponsor: NorthShore University Health System

Obstructed DefecationPelvic Organ Prolapse

CompletedInterventional · Phase 3NCT05754957 ↗

A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome

Robert M MinutelloPIDmitriy N. FeldmanPI

Intervention: Drug: Milvexian · Other: Placebo
Dates: Apr 2023 – Feb 2026
Sponsor: Janssen Research & Development, LLC

Acute Coronary Syndrome

‹ Prev 1 2 3 4 5…56 57 58 59 60 Next ›